Zheng Quan Zhi Xing·2025-08-21 16:58Core Points - The company held its 13th meeting of the third Supervisory Board on August 21, 2025, via telecommunication, which complied with relevant laws and regulations [1] - The Supervisory Board approved the full semi-annual report for 2025, confirming its compliance with legal standards and accuracy [1][2] - The company plans to invest an additional $10.5 million in its joint venture in Singapore, PharmaGend Global Medical Services Pte. Ltd., to support infrastructure and operational needs [3][4] - The adjustments to the stock incentive plans for 2021, 2022, and 2023 were approved, ensuring compliance with relevant regulations and not harming shareholder interests [5][6] - The board confirmed that the conditions for the fourth vesting period of the 2021 stock incentive plan were met, but the stocks will remain unsold until January 26, 2026 [6] - The conditions for the third vesting period of the 2022 stock incentive plan were also met, with stocks remaining unsold until January 27, 2026 [7] - The board agreed to void unvested stocks from the 2021, 2022, and 2023 incentive plans due to the departure of certain employees and unmet performance targets [8][9]